Thirty-five out of every 100 job applicants in the pharmaceutical or clinical trial space in India “are lying about their credentials”, says a report by Delhi-based employee screening firm AuthBridge.
Thirty-five out of every 100 job applicants in the pharmaceutical or clinical trial space in India “are lying about their credentials”, says a report by Delhi-based employee screening firm AuthBridge.
According to a report in India’s Economic Times, AuthBridge sifted through three years of applicant data from over 500 companies and found that pharma/clinical trials is among the industries with the “highest employee discrepancies”.
The trend is said to be most common among the 30-49 age groups, when “the applicant doesn’t mind enriching his or her educational qualification,” says AuthBridge CEO, Ajay Trehan.
He goes on: “One candidate had furnished the educational qualifications of his ex-boss, another had used her deceased sister’s credentials while applying for a job.”
Pharma sector hiring grew by 24% last year compare with 2012, according to a report by headhunting firm Randstad. But most of the recent hires in senior positions are from outside the industry, noted a spokesperson for a large Indian pharma firm, because there is uncertainty about the quality of people available in the current market. In areas such as R&D, however, research and development, there are no options but to look for those within the industry. As a result, this particular executive’s firm has “tightened investigation of our potential employees.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
AbbVie’s Emraclidine Fails to Reduce Schizophrenia Symptoms Compared to Placebo
November 11th 2024Results from the Phase II EMPOWER trial found that emraclidine failed to meet its primary endpoint of reducing Positive and Negative Syndrome Scale scores after six weeks of treatment for schizophrenia.